An evaluation of managed entry agreements in Belgium: A system with threats and (high) potential if properly applied-Reference-Cited by-同舟云学术

An evaluation of managed entry agreements in Belgium: A system with threats and (high) potential if properly applied

Published:2020-09 Issue:9 Volume:124 Page:959-964
ISSN:0168-8510
Container-title:Health Policy
language:en
Short-container-title:Health Policy

Author:

Neyt Mattias,Gerkens Sophie,San Miguel Lorena,Vinck Irm,Thiry Nancy,Cleemput Irina

Publisher

Elsevier BV

Subject

Health Policy

Reference15 articles.

1. Managed entry agreements for pharmaceuticals: the European experience;Ferrario,2013

2. Linking payment to health outcomes: a taxonomy and examination of performance-based reimbursement schemes between healthcare payers and manufacturers;Carlson;Health Policy (New York),2010

3. How to improve the Belgian process for Managed Entry Agreements? An analysis of the Belgian and international experience. Health Services Research (HSR);Gerkens,2017

4. Reconciling uncertainty of costs and outcomes with the need for access to orphan medicinal products: a comparative study of managed entry agreements across seven European countries;Morel;Orphanet J Rare Dis,2013

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Creating win-win-win situations with managed entry agreements? Prioritizing gene and cell therapies within the window of opportunity;Drug Discovery Today;2024-07

2. Financial Outcomes of Managed Entry Agreements for Pharmaceuticals in Italy;JAMA Health Forum;2023-12-28

3. Pharmaceutical pricing and managed entry agreements: An exploratory study on future perspectives in Europe;Health Policy and Technology;2023-09

4. Goals and methods of managed entry agreements – can we get what we want?;Health Policy and Technology;2023-06

5. Belgian observational survival data (incidence years 2004–2017) and expenditure for innovative oncology drugs in twelve cancer indications;European Journal of Cancer;2023-03